Company

Anthera Pharmaceuticals

As of the edition of 20 October 2026, Anthera Pharmaceuticals runs 4 drugs; it is on route A at 4 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

Route A at 4 targets, route B at 0 targets.

Three of its 4 rows, by target and route
Target	Route
TNFSF13B Tumor necrosis factor ligand superfamily member 13B	Route A
PLA2G10 Group 10 secretory phospholipase A2	Route A
PLA2G2A Phospholipase A2, membrane associated	Route A

In the product

4 company-target rows on route A or B; 1 is not shown here, and no score is.